NMG is a subgroup of AWMSG. Up to ten NMG meetings are scheduled per year, which are held in private. NMG considers the clinical and cost-effectiveness of a medicine, along with written evidence from the pharmaceutical company, clinical experts in the field and relevant patient organisation(s)/support group(s)/patient(s)/patient carer(s). NMG makes a preliminary recommendation to AWMSG in relation to each medicine undergoing appraisal.
For further information on the roles and responsibilities of NMG in relation to the therapeutic appraisal process, please refer to the Frequently Asked Questions